Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE), is highly active against primary uterine serous papillary carcinoma cell lines in vitro

American Journal of Obstetrics and Gynecology

Volumn 214, Issue 1, 2016, Pages 99.e1-99.e8

  Bellone, Stefania ^a   Black, Jonathan ^a   English, Diana P ^a   Schwab, Carlton L ^a   Lopez, Salvatore ^a   Cocco, Emiliano ^a   Bonazzoli, Elena ^a   Predolini, Federica ^a   Ferrari, Francesca ^a   Ratner, Elena ^a   Silasi, Dan Arin ^a   Azodi, Masoud ^a   Schwartz, Peter E ^a   Santin, Alessandro D ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

bispecific antibody; CD3; EpCAM; T lymphocyte; uterine serous cancer

Indexed keywords

BIOLOGICAL MARKER; CARBOXYFLUORESCEIN; CARBOXYFLUORESCEIN SUCCINIMIDYL ESTER; CD4 ANTIGEN; CD8 ANTIGEN; CYTOKINE; EPITHELIAL CELL ADHESION MOLECULE; HLA DR ANTIGEN; INTERLEUKIN 2 RECEPTOR ALPHA; SOLITOMAB; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BISPECIFIC ANTIBODY; CD3 ANTIGEN; CELL ADHESION MOLECULE; EPCAM PROTEIN, HUMAN; TUMOR ANTIGEN;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; ASCITES; ASCITES FLUID; CANCER CELL LINE; CANCER PATIENT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL KILLING; CHROMIUM RELEASE ASSAY; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENDOMETRIUM CARCINOMA; EX VIVO STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOMODULATION; IN VITRO STUDY; LYMPHOCYTE PROLIFERATION; NATURAL KILLER CELL; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION; CARCINOMA, PAPILLARY; CELL PROLIFERATION; CELL SURVIVAL; CHEMISTRY; COCULTURE; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DRUG EFFECTS; FEMALE; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; NEOPLASMS, CYSTIC, MUCINOUS, AND SEROUS; PATHOLOGY; TUMOR CELL LINE; UTERINE NEOPLASMS;

ANTIBODIES, BISPECIFIC; ANTIGENS, CD3; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; ASCITIC FLUID; CARCINOMA, PAPILLARY; CD4-POSITIVE T-LYMPHOCYTES; CELL ADHESION MOLECULES; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; COCULTURE TECHNIQUES; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; EPITHELIAL CELL ADHESION MOLECULE; FEMALE; FLOW CYTOMETRY; HUMANS; LYMPHOCYTE ACTIVATION; NEOPLASMS, CYSTIC, MUCINOUS, AND SEROUS; T-LYMPHOCYTES, CYTOTOXIC; UTERINE NEOPLASMS;

EID: 84955441701     PISSN: 00029378     EISSN: 10976868     Source Type: Journal    
DOI: 10.1016/j.ajog.2015.08.011     Document Type: Article

References (27)

1. R.L. Siegel, K.D. Miller, and A. Jemal Cancer statistics, 2015 CA Cancer J Clin 65 2015 5 29
2. M. Hendrickson, J. Ross, P. Eifel, A. Martinez, and R. Kempson Uterine papillary serous carcinoma: a highly malignant form of endometrial adenocarcinoma Am J Surg Pathol 6 1982 93 108
3. B.M. Slomovitz, T.W. Burke, P.J. Eifel, and et al. Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases Gynecol Oncol 91 2003 463 469
4. B.A. Goff, D. Kato, R.A. Schmidt, and et al. Uterine papillary serous carcinoma: patterns of metastatic spread Gynecol Oncol 54 1994 264 268
5. J.L. Nicklin, and L.J. Copeland Endometrial papillary serous carcinoma: patterns of spread and treatment Clin Obstet Gynecol 39 1996 686 695
6. S. Zhao, M. Choi, J.D. Overton, and et al. Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma Proc Natl Acad Sci U S A 110 2013 2916 2921
7. A.D. Santin, F. Zhan, S. Bellone, and et al. Discrimination between uterine serous papillary carcinomas and ovarian serous papillary tumours by gene expression profiling Br J Cancer 90 2004 1814 1824
8. A.D. Santin, F. Zhan, S. Cane, and et al. Gene expression fingerprint of uterine serous papillary carcinoma: identification of novel molecular markers for uterine serous cancer diagnosis and therapy Br J Cancer 92 2005 1561 1573
9. M. Munz, P.A. Baeuerle, and O. Gires The emerging role of EpCAM in cancer and stem cell signaling Cancer Res 69 2009 5627 5629
10. A. Armstrong, and S.L. Eck EpCAM: a new therapeutic target for an old cancer antigen Cancer Biol Ther 2 2003 320 326
11. K. Brischwein, B. Schlereth, B. Guller, and et al. MT110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors Mol Immunol 43 2006 1129 1143
12. S. Bellone, E.R. Siegel, E. Cocco, and et al. Overexpression of epithelial cell adhesion molecule in primary, metastatic, and recurrent/chemotherapy-resistant epithelial ovarian cancer: implications for epithelial cell adhesion molecule-specific immunotherapy Int J Gynecol Cancer 19 2009 860 866
13. C.E. Richter, E. Cocco, S. Bellone, and et al. High-grade, chemotherapy-resistant ovarian carcinomas overexpress epithelial cell adhesion molecule (EpCAM) and are highly sensitive to immunotherapy with MT201, a fully human monoclonal anti-EpCAM antibody Am J Obstet Gynecol 203 2010 582.e1 582.e7
14. M. Balzar, M.J. Winter, C.J. de Boer, and S.V. Litvinov The biology of the 17-1A antigen (Ep-CAM) J Mol Med 77 1999 699 712
15. N.K. Spurr, H. Durbin, D. Sheer, M. Parkar, L. Bobrow, and W.F. Bodmer Characterization and chromosomal assignment of a human cell surface antigen defined by the monoclonal antibody AUAI Int J Cancer 38 1986 631 636
16. P.M. McLaughlin, M.C. Harmsen, W.H. Dokter, and et al. The epithelial glycoprotein 2 (EGP-2) promoter-driven epithelial-specific expression of EGP-2 in transgenic mice: a new model to study carcinoma-directed immunotherapy Cancer Res 61 2001 4105 4111
17. B. Schlereth, I. Fichtner, G. Lorenczewski, and et al. Eradication of tumors from a human colon cancer cell line and from ovarian cancer metastases in immunodeficient mice by a single-chain Ep-CAM-/CD3-bispecific antibody construct Cancer Res 65 2005 2882 2889
18. D.P. English, S. Bellone, C.L. Schwab, and et al. Solitomab, an epithelial cell adhesion molecule/CD3 bispecific antibody (BiTE), is highly active against primary chemotherapy-resistant ovarian cancer cell lines in vitro and fresh tumor cells ex vivo Cancer 121 2015 403 412
19. S. Radoja, M. Saio, D. Schaer, M. Koneru, S. Vukmanovic, and A.B. Frey CD8(+) tumor-infiltrating T cells are deficient in perforin-mediated cytolytic activity due to defective microtubule-organizing center mobilization and lytic granule exocytosis J Immunol 167 2001 5042 5051
20. M. Bocchia, V. Bronte, M.P. Colombo, and et al. Antitumor vaccination: where we stand Haematologica 85 2000 1172 1206
21. R.T. Costello, J.A. Gastaut, and D. Olive Tumor escape from immune surveillance Arch Immunol Ther Exper 47 1999 83 88
22. J.G. Sinkovics, and J.C. Horvath Vaccination against human cancers (review) Int J Oncol 16 2000 81 96
23. W.M. Fiedler, M. Kebenko, M.-E. Goebeler, and et al. A phase I study of EpCAM/CD3-bispecific antibody (MT110) in patients with advanced solid tumors. Oral Abstract Session, Developmental Therapeutics: Clinical Pharmacology and Immunotherapy Oral Abstract Session June 1-5, 2012 Presented at the ASCO Annual Meeting Chicago, IL
24. A. Burges, P. Wimberger, C. Kumper, and et al. Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody: a phase I/II study Clin Cancer Res 13 2007 3899 3905
25. M.S. Topp, N. Gokbuget, G. Zugmaier, and et al. Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia J Clin Oncol 32 2014 4134 4140
26. M. Sanford Blinatumomab: first global approval Drugs 75 2015 321 327
27. E. Oak, and N.L. Bartlett Blinatumomab for the treatment of B-cell lymphoma Expert Opin Investig Drugs 2015 1 10